You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
三鑫醫療(300453.SZ)及子公司變更醫療器械生產許可證
格隆匯 12-17 18:20

格隆匯12月17日丨三鑫醫療(300453.SZ)公佈,公司與控股子公司寧波菲拉爾醫療用品有限公司(“寧波菲拉爾”)於近日完成了各自《醫療器械生產許可證》的變更手續,分別取得了由江西省藥品監督管理局、浙江省藥品監督管理局換髮後的《醫療器械生產許可證》。

一、醫療器械生產許可證的基本情況

1、企業名稱:江西三鑫醫療科技股份有限公司

許可證編號:贛食藥監械生產許20150058號;法定代表人:彭義興;企業負責人:彭義興;住所:江西省南昌縣小藍經濟開發區富山大道999號生產地址:江西省南昌縣三江鎮三江大道339號;江西省南昌縣小藍經濟開發區富山大道999號;

生產範圍:舊版分類編碼-Ⅱ類:6815-注射穿刺器械,6821-醫用電子儀器設備,6823-4-其他,6856-病房護理設備及器具,6864-2-輔料、護創材料,6866-醫用高分子材料及製品;舊版分類編碼-Ⅲ類:6815-注射穿刺器械,6821-醫用電子儀器設備,6845-4-血液淨化設備和血液淨化器具,6845-7透析粉、透析液,6866-1-輸液、輸血器具及管路,6877-介入器材;

新版分類編碼-Ⅱ類:06-08超聲影像診斷附屬設備,08-05呼吸、麻醉、急救設備輔助裝置,08-06呼吸、麻醉用管路、面罩,14注輸、護理和防護器械,18-01婦產科手術器械;新版分類編碼-Ⅲ類:03-13神經和心血管手術器械-心血管介入器械,07-10附件、耗材,10-02血液分離、處理、貯存器具,10-04血液淨化及腹膜透析器具,14注輸、護理和防護器械,22-11採樣設備和器具***;

有效期限:至2020年10月18日;發證部門:江西省藥品監督管理局;發證日期:2019年12月10日;

2、企業名稱:寧波菲拉爾醫療用品有限公司

許可證編號:浙食藥監械生產許20140201號;法定代表人:趙嬋娟企業負責人:沈俊波;住所:寧波市餘姚市陸埠鎮鐘山東路148弄2號;生產地址:寧波市餘姚市陸埠鎮鐘山東路148弄2號;生產範圍:第Ⅲ類:10-02-血液分離、處理、貯存器具,10-06-心肺轉流器具***;有效期限:至2024年9月8日;發證部門:浙江省藥品監督管理局;發證日期:2019年12月10日。

因公司廠房擴建,擴建後的倉儲場地已基本滿足目前實際的倉儲容量需求。因此,公司申請刪減原《醫療器械生產許可證》登載的一處生產地址:江西省南昌縣小藍經濟開發區金沙一路1069號(倉庫)。公司調整倉儲佈局,進一步提升了公司倉儲管理效率,有利於降低倉儲成本。

根據原國家食品藥品監督管理總局發佈的《關於發佈醫療器械分類目錄的公告》(2017年第104號)和《關於實施 <醫療器械分類目錄> 有關事項的公告》(2017年143號)有關規定,新的《醫療器械分類目錄》自2018年8月1日起實施,主管部門應當依據醫療器械註冊證將《醫療器械生產許可證》的生產範圍和醫療器械生產產品登記表分成原《醫療器械分類目錄》分類編碼區和新《醫療器械分類目錄》分類編碼區,並明確標識,分別註明產品生產範圍。待全部產品均為新版產品分類編碼的註冊證後,不再分區。寧波菲拉爾目前持有的醫療器械註冊證均為按新《醫療器械分類目錄》核發的註冊證。因此,寧波菲拉爾此次換髮的《醫療器械生產許可證》登載的生產範圍均為新版產品分類編碼。

公司及寧波菲拉爾此次分別變更生產地址及生產範圍(產品分類編碼)並分別換髮《醫療器械生產許可證》,不會對公司及寧波菲拉爾的生產經營產生重大影響。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account